Moder’s Post

Average lengths of stay and common complications are just some of the factors care teams should consider when evaluating the costs of #TAVR and SAVR.

Bling in the New Year with Xcitium! We're gearing up for end of year and want to win big with our Partners 🤩Reach out to Nick Loggia Jr. (East) or I to learn more on our how our #ZeroDwellContainment is disrupting the EDR, MDR, & XDR space and what fantastic resources we're building into our next-gen channel program 🌟 #Xcitium #XcitiumChannel #XcitiumPartners #NextGenChannel

TG and Atherosclerosis. 👉Postprandial triglycerides are part of the problem and will have to be definitively addressed in the fight against the atherosclerotic process and residual VR.

🌐 Elevate Your Brand with RXWG.com – A Premium Domain! 🚀 Perfect for creating a memorable online presence, this versatile and easy-to-remember domain is ideal for any business looking to stand out. Don't miss out – own a piece of prime digital real estate today! Visit RXWG.com now and see for yourself! #DomainForSale #DomainDeal #DomainNames #DomainsForSale

Several market players such as Novo Nordisk and Boston Immune Technologies and Therapeutics are involved in #mergersandacquisitions activities. Click @ https://lnkd.in/d_vZ226Q to capitalize on emerging opportunities that drive innovation in prediabetes management solutions. #gvr #healthcare #healthcareindustry #prediabetes #diabetes

PharmAust might just be that 1 in 1000 company! This morning, PharmAust CEO Michael Thurn shared some big news. They've begun giving doses in the Open Label Extension study to the 12 participants from the MEND #Phase1 trial for Motor Neurone Disease (#MND / #als ).   In addition, they've revealed some key findings from #statisticalmodeling, which suggest a significant benefit in terms of survival. Simply put, if 12 similar MND patients were not treated at all, the chances of any of them surviving 12 months would be less than 0.1% or 1 in 1000. This analysis came from experts in statistics and PharmAust's partner, Berry Consultants, LLC.   Looking at it another way, PharmAust has defied the odds as not one of the patients involved in their Phase 1 clinical trial for MND has passed away, some 15 months after the start of the clinical trial. The fact that all 12 patients have maintained their ability to swallow is a great data point.    Statistically, there was a 99.9% chance at least one of the patients would NOT have survived 12 12-month Phase 1 clinical trial. To put this into context, a recently FDA-approved drug for ALS/MND, called RELYVRIO, showed a survival rate of around 75% in its 48-week trial.   PharmAust has also informed the market that the Phase 1 Clinical Trial results are expected this quarter. This is an exciting moment where solid data may back up anecdotal evidence.   From a recent roadshow presentation (below), there is a great graphic illustrating the typical progression of MND/ALS. The average survival time from diagnosis is approximately two years. The fact that all participants in PharmAust's MND Phase 1 trial can still swallow suggests, anecdotally, that there has been little decline in the group of 12 over the last 15 months. #biotechnology #motorneuronedisease #asxnews Roger Aston Sam Wright Robert C Bishop John Clark Blue Ocean Equities is the corporate advisor to PharmAust Limited Video Presentation to investors

#EPICis10: As we commemorate ten years of taking the problem out of gambling, highlighting our growth in the ever-evolving US market is a key part of our story. In this special feature, members of our US-based team explain what drew them to EPIC and why they take so much pride in what we continue to achieve. #gambling #gamblingharm #harmprevention #problemgambling